Publications by authors named "S Gordhandas"
Objectives: Women with germline BRCA1/2 pathogenic variants (gBRCA1/2) are recommended to undergo annual breast MRI and mammography. Our objective was to describe the frequency of insurance denials for annual breast MRIs in women with gBRCA1/2 and determine denial trends.
Methods: Women with gBRCA1/2 following in a high-risk breast cancer clinic with breast MRIs ordered from 2020 to 2021 were identified and cross-referenced with a database of insurance denials.
Objectives: To develop a pre-operative tool to estimate the risk of peri-operative packed red blood cell transfusion in primary debulking surgery.
Methods: We retrospectively reviewed an institutional database to identify patients who underwent primary debulking surgery for ovarian cancer at a single center between January 1, 2001 and May 31, 2019. Receiver operating characteristic curve and area under the receiver operating characteristic curve (AUC) were calculated.
Article Synopsis
- - The study investigates the expression of folate receptor alpha (FRα) in ovarian low-grade serous carcinoma (LGSC) and its potential as a therapeutic target for treatment with mirvetuximab soravtansine.
- - Out of 89 LGSC samples examined, 40% showed high FRα expression, with no significant links found between FRα levels and patient age, race, or survival outcomes.
- - The presence of high FRα expression was more common in LGSCs without genetic alterations in the MAPK pathway, indicating that FRα testing could be useful for selecting patients for targeted therapies.
•Both primary endometrial cancers (ECs) and matched lung metastases shared a common ancestor with independent evolution at each site.•The two endometrioid ECs studied acquired additional mutations during the distant metastatic process.•Subclonal hotspot mutations in the two primary ECs studied became clonal in the distant metastases.
View Article and Find Full Text PDFObjective: To evaluate the theoretical impact of regionalizing cytoreductive surgery for ovarian cancer (OC) to high-volume facilities on patient travel.
Methods: We retrospectively identified patients with OC who underwent cytoreduction between 1/1/2004-12/31/2018 from the New York State Cancer Registry and Statewide Planning and Research Cooperative System. Hospitals were stratified by low-volume (<21 cytoreductive surgical procedures for OC annually) and high-volume centers (≥21 procedures annually).